Clinical Trial: Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07518329) titled 'Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.' on Feb. 19.

Brief Summary: Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Non Hodgkin Lymphoma (NHL) Leukaemia

Intervention: DRUG: ALA-101

Single IV infusion of ALA-101 post chemotherapy conditioning with Fludarabine and Cyclophosphamide

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Arovella Therapeutics Ltd

Published by HT Digital Content Services with permissi...